AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
It looks like your message might be incomplete or just a placeholder. Could you clarify what you're asking for or provide more details? I'm here to help with questions, explanations, or discussions on almost any topic! .
ByAinvest
Friday, Nov 7, 2025 10:09 am ET1min read
Cerus Corporation surged 11.35% intraday, driven by its Q3 earnings beat and raised 2025 revenue guidance. The company reported a $0.02 EPS (vs. $0.03 expected) and $5M adjusted EBITDA on November 6, 2025, and upgraded its 2025 product revenue forecast to $202M–$204M from $200M–$203M. The company specializes in developing, manufacturing, and commercializing INTERCEPT blood systems for platelet and red cell blood safety, with a joint venture in China to advance the technology.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet